AR057870A1 - Nitroderivados inhibidores de renina - Google Patents

Nitroderivados inhibidores de renina

Info

Publication number
AR057870A1
AR057870A1 ARP060104557A ARP060104557A AR057870A1 AR 057870 A1 AR057870 A1 AR 057870A1 AR P060104557 A ARP060104557 A AR P060104557A AR P060104557 A ARP060104557 A AR P060104557A AR 057870 A1 AR057870 A1 AR 057870A1
Authority
AR
Argentina
Prior art keywords
group
formula
integer
ono2
defined above
Prior art date
Application number
ARP060104557A
Other languages
English (en)
Inventor
Nicoleta Almirante
Angela Monopoli
Ennio Ongini
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of AR057870A1 publication Critical patent/AR057870A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Tienen una actividad farmacologica más amplia y una capacidad de tolerancia mejorada. Pueden emplearse para tratar o prevenir la falla cardíaca congestiva, las enfermedades coronarias, la insuficiencia cardíaca, la disfuncion y la hipertrofia del ventrículo izquierdo, la fibrosis cardíaca, la isquemia de miocardio, el infarto, la aterosclerosis, la restenosis posterior a angioplastía, la insuficiencia renal, la isquemia renal, la falla renal, la fibrosis renal, la glomerulonefritis, el colico renal, la hipertension ocular y pulmonar, el glaucoma, la hipertension, las complicaciones diabéticas, tales como la nefropatía, la vasculopatía y la neuropatía, las enfermedades vasculares periféricas, la fibrosis hepática, la hipertension portal, los síndromes metabolicos, la disfuncion eréctil, las complicaciones posteriores a cirugías vasculares o cardíacas, las complicaciones del tratamiento con agentes inmunosupresores posterior a un transplante de organos, el hiperaldosteronismo, la fibrosis pulmonar, el escleroderma, la ansiedad, los trastornos cognitivos. Reivindicacion 1: Un compuesto de formula general (1), o una sal o un estereoisomero de éste aceptable para el uso farmacéutico: A-(X0-ONO2)s caracterizado porque s es un numero entero igual a 1 o 2; A se selecciona entre los siguientes grupos (1a) a (1s), donde N1 es -O- o -OH; N2 es -O-, -NH-, o N3 donde N3 es -NH2 o -OH; con la condicion de que al menos uno de N1 y N2 es un grupo -O- o -NH-, capaz de unirse a X0; X0 es igual a -X1-Y-, donde X1 es -CO- o -COO-; Y es un radical bivalente que tiene el siguiente significado: a) C1-20 alquileno recto o ramificado, preferiblemente C1-10, que está opcionalmente sustituido con uno o más de los sustituyentes seleccionados del grupo que consiste en: átomos de halogeno, hidroxilo, -ONO2 o T0, donde T0 es -OC(O)(C1-10 alquil)-ONO2 o -O(C1-10 alquil)-ONO2; -cicloalquileno con entre 5 y 7 átomos de C en el anillo de cicloalquileno, donde el anillo está opcionalmente sustituido con cadenas laterales T, donde T es un alquilo recto o ramificado con entre 1 y 10 átomos de C, preferiblemente CH3; b) un grupo de formula (2); c) un grupo de formula (3) donde n es un numero entero entre 0 y 20, y n1 es un numero entero entre 1 y 20; d) un grupo de formula (4) donde n 1es como se definio con anterioridad y n2 es un numero entero entre 0 y 2; X2 = -OCO- o -COO- y R2 es H o CH3; e) un grupo de formula (5) donde n1, n2, R2 y X2 son como se definio con anterioridad; Y1 es -CH2-CH2- o -CH=CH-(CH2)n2-; f) un grupo de formula (6) donde n1 y R2 son como se definio con anterioridad, R3 es H o -COCH3; con la condicion de que, cuando Y se selecciona entre los radicales bivalentes mencionados en b)-f), el grupo -ONO2 está unido a un grupo -(CH2)n1; g) un grupo de formulas (7) donde X3 es -O- o -S-, n3 es un numero entero entre 1 y 6, preferentemente entre 1 y 4, R2 es como se definio con anterioridad; h) un grupo de formula (8) donde n4 es un numero entero entre 0 y 10; n5 es un numero entero entre 1 y 10; R4, R5, R6, R7 son iguales o diferentes, y son H o C1-4 alquilo recto o ramificado, preferentemente R4, R5, R6, R7 son H; donde el grupo -ONO2 está unido al grupo de formula (9) donde n5 es como se definio con anterioridad; Y2 es un anillo heterocíclico saturado, no saturado o aromático de 5 o 6 miembros, que contiene uno o más heteroátomos seleccionados entre N, O, S y se selecciona entre los grupos (Y1) a (Y13).
ARP060104557A 2005-10-18 2006-10-18 Nitroderivados inhibidores de renina AR057870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72755005P 2005-10-18 2005-10-18

Publications (1)

Publication Number Publication Date
AR057870A1 true AR057870A1 (es) 2007-12-26

Family

ID=37653227

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104557A AR057870A1 (es) 2005-10-18 2006-10-18 Nitroderivados inhibidores de renina

Country Status (6)

Country Link
US (1) US20080274171A1 (es)
EP (1) EP1934186A2 (es)
JP (1) JP2009514809A (es)
AR (1) AR057870A1 (es)
CA (1) CA2626568A1 (es)
WO (1) WO2007045551A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
WO2008098992A1 (en) * 2007-02-16 2008-08-21 Novartis Ag Use of organic compounds
TW200932241A (en) 2007-12-05 2009-08-01 Speedel Experimenta Ag Organic compounds
AU2011243947A1 (en) * 2010-04-23 2012-12-06 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW198712B (es) * 1991-04-17 1993-01-21 Hoffmann La Roche
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) * 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
DE602004019779D1 (de) * 2003-06-19 2009-04-16 Nicox Sa Enalapril-nitroxy-derivate und verwandte verbindungen als ace-hemmer zur behandlung von kardiovaskulären erkrankungen
CA2536967A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use

Also Published As

Publication number Publication date
US20080274171A1 (en) 2008-11-06
WO2007045551A2 (en) 2007-04-26
EP1934186A2 (en) 2008-06-25
WO2007045551A3 (en) 2007-06-07
JP2009514809A (ja) 2009-04-09
CA2626568A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
ECSP21000990A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
RU2008145701A (ru) Производные пурина для применения в качестве агонистов аденозинового рецептора a2a
AR106041A1 (es) Moduladores de la proteína core de la hepatitis b
AR057870A1 (es) Nitroderivados inhibidores de renina
AR108325A1 (es) Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
UY35401A (es) ?compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca?.
AR056868A1 (es) Nitrooxi derivados de esteroides, composiciones farmaceuticas y su uso para tratar trastornos de la piel o de la membrana mucosa
AR033678A1 (es) Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR044561A1 (es) Derivados de estatina
AR057414A1 (es) Derivados de prostaglandina
AR047081A1 (es) Derivados de prostaglandinas, metodos para su preparacion, composiciones farmaceuticas que las contienen y su uso en el tratamiento del glaucoma y de la hipertension ocular.
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
AR120682A1 (es) Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
AR058180A1 (es) Indeno derivados, su preparacion y su uso como medicamentos
RU2009115653A (ru) Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA202092975A1 (ru) Селективные супрессоры рецептора эстрогена
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
RU2008145704A (ru) Пуриновые производные в качестве агонистов a2a-рецептора
AR072233A1 (es) Derivados de acido lipoico y composiciones farmaceuticas que los contienen y metodos para tratar una enfermedad
UY39559A (es) Compuestos y su uso
AR061598A1 (es) Nitroderivados heterociclicos como antagonistas de receptor de endotelina

Legal Events

Date Code Title Description
FB Suspension of granting procedure